Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.61 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.60 |
| ▸ | PARP1 | P09874 | 1/20 | 0.60 |
| ▸ | THRB | P10828 | 2/20 | 0.59 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.58 |
| ▸ | PRSS1 | P07477 | 6/20 | 0.57 |
| ▸ | TNKS | O95271 | 1/20 | 0.57 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.57 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.57 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.57 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.57 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.57 |
| ▸ | THRA | P10827 | 1/20 | 0.56 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL203104 | 0.95 | SMPD1 (0.68) | KMT2ASMPD1PLA2G4BPARP1THRB | |
| SCHEMBL202777 | 0.94 | SMPD1 (0.70) | KMT2ASMPD1PLA2G4BPARP1THRB | |
| SCHEMBL202638 | 0.94 | SMPD1 (0.70) | KMT2ASMPD1PLA2G4BPARP1THRB | |
| SCHEMBL14421817 | 0.94 | SMPD1 (0.70) | KMT2ASMPD1PLA2G4BPARP1THRB | |
| SCHEMBL204298 | 0.94 | SMPD1 (0.70) | KMT2ASMPD1PLA2G4BPARP1THRB | |
| SCHEMBL201242 | 0.94 | SMPD1 (0.70) | KMT2ASMPD1PLA2G4BPARP1THRB | |
| SCHEMBL12951117 | 0.94 | SMPD1 (0.70) | KMT2ASMPD1PLA2G4BPARP1THRB | |
| SCHEMBL201524 | 0.92 | KMT2A (0.73) | KMT2ASMPD1PARP1NR1H4PRSS1 | |
| SCHEMBL31609710 | 0.90 | PLA2G4B (0.58) | KMT2ASMPD1PLA2G4BPARP1THRB | |
| SCHEMBL202778 | 0.90 | PLA2G4B (0.58) | KMT2ASMPD1PLA2G4BPARP1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1429108-A | Phosphate transport inhibitors | SMITHKLINE BEECHAM CORP (US) | 2003-07-09 | — | — | CN | claimed |
| JP-H09510704-A | — | — | 1997-10-28 | — | — | JP | claimed |
| EP-0749415-A1 | BENZAMIDE ANALOGS, USEFUL AS PARP (ADP-RIBOSYLTRANSFERASE, ADPRT) DNA REPAIR ENZYME INHIBITORS | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 1996-12-27 | — | — | EP | claimed |
| WO-1995024379-A1 | BENZAMIDE ANALOGS, USEFUL AS PARP (ADP-RIBOSYLTRANSFERASE, ADPRT) DNA REPAIR ENZYME INHIBITORS | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 1995-09-14 | — | — | WO | claimed |
| US-20250179008-A1 | ANTIBACTERIAL AGENTS | TAXIS PHARMACEUTICALS, INC. (US) | 2025-06-05 | — | — | US | disclosed |
| EP-3508484-B1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2021-04-07 | — | — | EP | disclosed |
| EP-3342771-B1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-11-25 | — | — | EP | disclosed |
| WO-2020212227-A1 | PROCESS FOR THE PRODUCTION OF SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO]ALKANEAMIDE DERIVATIVES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2020-10-22 | — | — | WO | disclosed |
| EP-3375780-B1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-06-03 | — | — | EP | disclosed |
| EP-3508484-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2019-07-10 | — | — | EP | disclosed |
| US-10272074-B2 | Inhibitors of glucocorticoid receptor translocation | Sanford Burnham Prebys Medical Discovery Institute (US) | 2019-04-30 | — | — | US | disclosed |
| US-20180207140-A1 | Pyrazolopyrimidines as Inhibitors of Glucocorticoid Receptor Translocation | Sanford Burnham Prebys Medical Discovery Institute | 2018-07-26 | — | — | US | disclosed |
| US-5543275-A | PYRAZOLO(1,5-B)(1,2,4)TRIAZOLE MAGENTA COUPLER | FUJI PHOTO FILM CO., LTD. (JP) | 1996-08-06 | — | — | US | disclosed |
| US-5534390-A | Silver halide color photographic material | FUJI PHOTO FILM CO., LTD. (JP) | 1996-07-09 | — | — | US | disclosed |
| WO-1995024379-A1 | BENZAMIDE ANALOGS, USEFUL AS PARP (ADP-RIBOSYLTRANSFERASE, ADPRT) DNA REPAIR ENZYME INHIBITORS | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 1995-09-14 | — | — | WO | disclosed |
| US-5223384-A | Multilayer; paper support, subbing and photosensitive layer | KONICA CORPORATION (JP) | 1993-06-29 | — | — | US | disclosed |
| EP-0256820-B1 | THERMAL DEVELOPING LIGHT-SENSITIVE MATERIAL | KONICA CORPORATION (JP) | 1992-07-29 | — | — | EP | disclosed |
| US-5032499-A | High density, stability | KONISHIROKU PHOTO INDUSTRY CO., LTD. (JP) | 1991-07-16 | — | — | US | disclosed |
| EP-0256820-A2 | Thermal developing light-sensitive material | KONICA CORPORATION (JP) | 1988-02-24 | — | — | EP | disclosed |
| US-4304935-A | Production of 1-phenyl-3-cyanoureas | REXOLIN CHEMICALS AB (SE) | 1981-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180207140-A1 | Pyrazolopyrimidines as Inhibitors of Glucocorticoid Receptor Translocation | NR3C1, NR3C2, GRK3 | KMT2A 3251/4885SMPD1 3149/4885PLA2G4B 2060/4885 |
| US-10272074-B2 | Inhibitors of glucocorticoid receptor translocation | NR3C1, NR3C2, GRK3 | KMT2A 3527/4885SMPD1 2511/4885PLA2G4B 1196/4885 |
| US-20250179008-A1 | ANTIBACTERIAL AGENTS | ALK, ROS1, NOX1 | KMT2A 1011/4885SMPD1 1055/4885PLA2G4B 4704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.